Xeno Biosciences

Xeno has a disruptive approach to treating obesity that mimics the highly successful treatment of gastric bypass surgery using a simple enteric-coated pill composed of components that have been shown to be safe in man. It induces the same microbiome changes caused by the surgery resulting in weight loss. Importantly, like the surgery, we anticipate that it will be effective in co-morbidities such as diabetes, CV and NASH in the obese population.